Ameriprise’s Sonnet BioTherapeutics SONN Stock Holding History

Ameriprise’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2	Closed	-$251K	–	3781
2019 Q1	$251K	Buy	+2	New	+$233K	﹤0.01%	3495

Other funds holding SONN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

QCIG

Quad-Cities Investment Group Davenport, Iowa $278M AUM 22.38% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Ameriprise's SONN Position: Q2 2019 in Review

Ameriprise sold out of Sonnet BioTherapeutics (SONN) in Q2 2019, closing a stake of 2 shares — an estimated $251K sold.

Ameriprise first reported a position in SONN in Q1 2019 and held it in 1 quarter. The position peaked at $251K in Q1 2019. 2 funds tracked by Wall St. Rank hold SONN as of Q2 2019.

Ameriprise reported no remaining Sonnet BioTherapeutics position as of Q2 2019 after selling out during the quarter.
Ameriprise sold 2 Sonnet BioTherapeutics shares in Q2 2019, an estimated $251K.
Ameriprise first reported a position in Sonnet BioTherapeutics in Q1 2019 and held it in 1 quarter.
Ameriprise's Sonnet BioTherapeutics position peaked at $251K in Q1 2019.
2 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2019.

Based on Ameriprise's 13F filing for Q2 2019, filed 14 Aug 2019.